Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
$36.35
+0.9%
$39.67
$26.20
$63.50
$1.66B1.43567,350 shs484,772 shs
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$18.53
+0.9%
$18.23
$13.30
$25.00
$443.06M1.122,774 shs7,303 shs
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$17.79
-1.0%
$15.98
$8.46
$25.29
$1.60B0.741.54 million shs1.05 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$26.47
+0.1%
$33.64
$24.28
$55.33
$1.60B2.361.98 million shs916,200 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-1.07%-3.62%-7.90%-10.75%-26.47%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
-0.25%+7.07%+2.37%+7.47%-15.67%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
+1.93%-0.44%+13.59%+14.46%+101.91%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-4.10%-7.68%-23.93%-6.07%-38.36%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
3.4638 of 5 stars
4.43.00.00.01.24.20.0
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
2.8024 of 5 stars
3.85.00.00.02.70.00.0
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2.5733 of 5 stars
3.43.00.00.02.70.80.6
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
4.1324 of 5 stars
3.42.00.04.44.00.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
2.86
Moderate Buy$99.00172.35% Upside
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
3.50
Strong Buy$45.00142.91% Upside
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2.87
Moderate Buy$32.2181.08% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.73
Moderate Buy$49.4086.63% Upside

Current Analyst Ratings Breakdown

Latest PRTC, APGE, TWST, and TVTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/11/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$90.00
8/10/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/7/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
8/7/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$30.00 ➝ $31.00
8/7/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$30.00 ➝ $32.00
8/4/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/4/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$46.00
7/7/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
7/7/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$90.00
7/7/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$100.00 ➝ $115.00
(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/AN/AN/AN/A$13.43 per shareN/A
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$4.83M92.55$2.41 per share7.70$17.04 per share1.09
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$233.18M6.80N/AN/A$0.37 per share48.08
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M5.11N/AN/A$7.92 per share3.34
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-$182.15M-$4.13N/AN/AN/AN/A-34.65%-32.76%N/A
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$27.78MN/A0.00N/AN/AN/AN/AN/A8/28/2025 (Estimated)
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$321.55M-$2.04N/AN/AN/A-50.64%-717.68%-30.69%10/30/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$1.45N/AN/AN/A-23.51%-29.03%-21.77%N/A

Latest PRTC, APGE, TWST, and TVTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-$1.03-$1.13-$0.10-$1.13N/AN/A
8/6/2025Q2 2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$0.28-$0.14+$0.14-$0.14$100.18 million$94.84 million
8/4/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54-$0.47+$0.07$0.33$95.52 million$96.06 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/AN/AN/AN/AN/A
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/AN/AN/AN/AN/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/A
16.36
16.36
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/A
9.33
9.33
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
9.50
2.00
1.98
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
3.90
3.60

Institutional Ownership

CompanyInstitutional Ownership
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
79.04%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.04%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
42.77%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
5.30%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
4.19%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
9146.11 million26.39 millionOptionable
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
10024.13 million22.85 millionNot Optionable
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
46089.14 million85.40 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99060.36 million58.54 millionOptionable

Recent News About These Companies

Twist Bioscience Appoints Trynka Shineman Blake to Board
Twist Bioscience: Headwinds Are Mounting
Twist Bioscience (TWST) Q3 Profit Surges

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apogee Therapeutics stock logo

Apogee Therapeutics NASDAQ:APGE

$36.35 +0.33 (+0.92%)
Closing price 04:00 PM Eastern
Extended Trading
$36.42 +0.07 (+0.19%)
As of 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

PureTech Health stock logo

PureTech Health NASDAQ:PRTC

$18.52 +0.17 (+0.90%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Travere Therapeutics stock logo

Travere Therapeutics NASDAQ:TVTX

$17.79 -0.18 (-1.00%)
Closing price 04:00 PM Eastern
Extended Trading
$17.79 0.00 (0.00%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$26.47 +0.02 (+0.08%)
Closing price 04:00 PM Eastern
Extended Trading
$26.43 -0.04 (-0.15%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.